Sugi Predict

Sugi Predict / Compounds / SCHEMBL1662641

SCHEMBL1662641

SCHEMBL1662641

COC(=O)[C@@H]1C=C(OS(=O)(=O)C(F)(F)F)CN1C(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 3/20 0.41
▸ NR1H2 P55055 6/20 0.39
▸ NR1H3 Q13133 5/20 0.39
▸ STS P08842 3/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ CCNT1 O60563 1/20 0.33
▸ CDK9 P50750 1/20 0.33
▸ HSD11B1 P28845 1/20 0.32
▸ MMP1 P03956 1/20 0.32
▸ MMP3 P08254 1/20 0.32
▸ MMP7 P09237 1/20 0.32
▸ MMP9 P14780 1/20 0.32
▸ PDE4B Q07343 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1662643 1.00 PTPN1 (0.41) PTPN1NR1H2NR1H3STSMEN1
SCHEMBL3557230 1.00 PTPN1 (0.41) PTPN1NR1H2NR1H3STSMEN1
SCHEMBL15388623 0.89 NR1H2 (0.34) PTPN1NR1H2NR1H3STSMEN1
SCHEMBL14857161 0.89 NR1H2 (0.34) PTPN1NR1H2NR1H3STSMEN1
SCHEMBL16050694 0.89 NR1H2 (0.40) PTPN1NR1H2NR1H3STSMEN1
SCHEMBL12295990 0.88 NR1H2 (0.34) PTPN1NR1H2NR1H3STSMEN1
SCHEMBL14857160 0.87 CXCR2 (0.32) —
SCHEMBL30683357 0.87 CXCR2 (0.32) —
SCHEMBL29289761 0.84 PTPN1 (0.39) PTPN1NR1H2NR1H3STSMEN1
SCHEMBL12248021 0.83 NR1H2 (0.35) PTPN1NR1H2NR1H3STSMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250320196-A1 APOL1 INHIBITORS AND METHODS OF USES THEREOF MAZE THERAPEUTICS INC (US) 2025-10-16 — — US disclosed
US-20250243187-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-07-31 — — US disclosed
EP-4551569-A1 ANTI-VIRAL COMPOUNDS Aligos Therapeutics, Inc. (US) 2025-05-14 — — EP disclosed
EP-4422618-A1 LOX ENZYME INHIBITING METHODS AND COMPOSITIONS Anovia Biosciences, Inc. (US) 2024-09-04 — — EP disclosed
US-12016864-B2 LOX enzyme inhibiting methods and compositions ANOVIA BIOSCIENCES, INC. (US) 2024-06-25 — — US disclosed
EP-4366831-A1 ANTI-VIRAL COMPOUNDS Aligos Therapeutics, Inc. (US) 2024-05-15 — — EP disclosed
CN-113135924-B Pyrimidine derivatives and their use in medicine 广东东阳光药业股份有限公司 2024-04-26 — — CN disclosed
CN-113072542-B ROR gamma t inhibitor and preparation method and application thereof 广东东阳光药业股份有限公司 2024-04-05 — — CN disclosed
US-20240109871-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-04-04 — — US disclosed
US-20240018126-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-01-18 — — US disclosed
US-20130287731-A1 HEPATITIS C VIRUS INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC 2013-10-31 — — US disclosed
EP-2306994-B1 S1P1 RECEPTOR AGONISTS AND USE THEREOF AMGEN INC (US) 2013-08-14 — — EP disclosed
US-20110224211-A1 Anti-Viral Compounds, Compositions, And Methods Of Use GLAXOSMITHKLINE LLC 2011-09-15 — — US disclosed
EP-2306994-A1 S1P1 RECEPTOR AGONISTS AND USE THEREOF Amgen, Inc (US) 2011-04-13 — — EP disclosed
US-7842685-B2 S1P1 receptor agonists and use thereof AMGEN INC. (US) 2010-11-30 — — US disclosed
WO-2010062821-A1 ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE GLAXOSMITHKLINE LLC (US) 2010-06-03 — — WO disclosed
US-20100029611-A1 S1P1 receptor agonists and use thereof AMGEN INC. (US) 2010-02-04 — — US disclosed
WO-2009154775-A1 S1P1 RECEPTOR AGONISTS AND USE THEREOF AMGEN INC. (US) 2009-12-23 — — WO disclosed
US-20050256166-A1 Nitrogen-containing compounds ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 — — US disclosed
EP-1535906-A1 NITROGEN-CONTAINING COMPOUNDS ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256166-A1 Nitrogen-containing compounds DPP4, DPP3, DPP8 PTPN1 164/4885NR1H2 3917/4885NR1H3 4287/4885
US-20250243187-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 PTPN1 1570/4885NR1H2 449/4885NR1H3 380/4885
US-20110224211-A1 Anti-Viral Compounds, Compositions, And Methods Of Use HAVCR2, SARS1, MAVS PTPN1 2134/4885NR1H2 1821/4885NR1H3 1230/4885
US-20130287731-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, SLC10A1, HCCS PTPN1 1289/4885NR1H2 349/4885NR1H3 200/4885
US-20100029611-A1 S1P1 receptor agonists and use thereof S1PR1, S1PR5, S1PR2 PTPN1 1228/4885NR1H2 51/4885NR1H3 71/4885
US-20250320196-A1 APOL1 INHIBITORS AND METHODS OF USES THEREOF APOL1, APOB, LDLR PTPN1 2316/4885NR1H2 16/4885NR1H3 20/4885
US-12016864-B2 LOX enzyme inhibiting methods and compositions LOX, LOXL1, LOXL2 PTPN1 1928/4885NR1H2 661/4885NR1H3 592/4885
US-20240018126-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 PTPN1 1570/4885NR1H2 449/4885NR1H3 380/4885
US-20240109871-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 PTPN1 1570/4885NR1H2 449/4885NR1H3 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.